JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target from $248 to $280.
JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $280
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.